Life Sciences Real Estate #16

Deep dive into Zurich, Daiichi Sankyo bets big on Munich, UPS Healthcare is chilling in Rome
Life Sciences Real Estate #16
Zurich photo by Henrique Ferreira / Unsplash
Life Sciences Real Estate #16
Zurich photo by Henrique Ferreira / Unsplash

Welcome subscribers,

In this edition, we take a close look at Zurich, the little big city that is ranked just behind the UK's Golden Triangle as a life sciences destination. Then it's off on the customary tour of European locations to see what's new. Please explore and enjoy!

Munich: Daiichi Sankyo bets big
Liverpool: city on a roll
Rome: UPS Healthcare is chilling
Cambridge: space is converted

Read more below for all the details.

Deep dive into Zurich

The Swiss city has lots to offer

Read the full article

Was this email forwarded to you? Did you know that you can subscribe to Life Sciences Real Estate and get access to all our resources?

New and extended assets

Daiichi Sankyo facility at Pfaffenhofen
Daiichi Sankyo facility at Pfaffenhofen


Japanese drugmaker Daiichi Sankyo announced its plans to invest approximately one billion euros (£860 million) to transform its Pfaffenhofen facility, located north of Munich, into an international innovation centre. The expansion aims to bolster the development and production of cutting-edge therapies, including treatments for breast, lung and stomach cancers, alongside cardiovascular drugs. The project, already underway, is slated for completion by 2030.


At the launch of its 2023 full-year results on 28 February, Primary Health Properties, the UK-listed company, revealed it had two active opportunities in Ireland worth €50 million (£43 million), compared to a UK development pipeline of just £14.8 million (€17.2 million). The locations were not revealed, although it seems likely that one is in Youghal, where planning permission was recently sought for the construction of a three-storey primary care centre.


UPS Healthcare announced a €55 million (£47 million) investment in two state-of-the-art facilities: one in Passo Corese near Rome’s Leonardo da Vinci-Fiumicino Airport and the other in Somaglia, near Milan. Spanning over 100,000 sq m (1.08 million sq ft), both feature advanced temperature-controlled technologies, necessary for biologics and specialty pharmaceuticals. The Passo Corese facility features a €15 million (£13 million) fleet of robots capable of autonomously picking and sorting 25,000 cases from 11-meter-high (36-feet-high) shelves. The warehouse has refrigerated cells that go down to -70°C.


Stoneshield Capital, through its DeepLabs platform specialising in life science and innovation, has initiated the development of the first science and innovation hub in Catalonia, known as BaSID (Barcelona Science Innovation District). This project, located in the towns of Sant Joan Despí and Esplugues de Llobregat, involves the acquisition of five properties totalling 75,000 sq m (807,300 sq ft). The most important properties acquired by the management company are Il-lumina, in Esplugues de Llobregat, and Bayer, in Sant Joan Despí. Total investment exceeds €200 million (£172 million).


Superlab Suisse is on track to open its new location in Basel in June, providing 4,770 sq m (51,344 sq ft) of lab and office space that is of fully fitted, serviced and ready to move into. The new building is located at Stuecki Park Basel, 15 minutes from the main train station and 10 minutes drive from the airport.


At Cambourne Park Science & Technology Campus, Building 2020 will be converted to deliver 10,109 sq ft (939 sq m) of fully fitted lab and write-up space across four suites. The park was acquired by Life Science REIT in 2021.


AstraZeneca plans to invest £450 million (€523 million) to research, develop and manufacture vaccines at its manufacturing site in Speke, a suburb of Liverpool, for the research, development, and manufacture of vaccines. A further £200 million (€233 million) investment was announced to expand AstraZeneca’s presence in Cambridge.


Healthcare provider Affidea will open a new clinic in Belfast. When finished, the clinic will offer a range of specialist medical services on-site including an ExpressCare clinic, several operating theatres, endoscopy services and consultant suites. It will also contain diagnostic imaging facility providing MRI, CT, Dexa, X-ray, mammography, fluoroscopy and ultrasound services. The diagnostic imaging department will have the capacity for up to 50,000 patients a year.


A groundbreaking ceremony for Nebula, a £40 million (€47 million) research and development scheme at Milton Park, took place in February 2024. Construction of the scheme’s seven buildings, ranging from 6,000 sq ft (560 sq m) to 13,000 sq ft (1,200 sq m), will see the substructure, structural frame and envelope delivered before the internal fit-out and finishing touches, with completion expected in winter 2024.


This section is for paying members only.

Stay on top of the life sciences real estate markets in Europe

Join us
Great! You’ve successfully signed up.
Welcome back! You've successfully signed in.
You've successfully subscribed to Life Sciences Real Estate.
Your link has expired.
Success! Check your email for magic link to sign-in.
Success! Your billing info has been updated.
Your billing was not updated.